arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

HCW Biologics Inc.

HCWB

$3.48 ▲ +0.08 (+2.50%) at close

7 Visible periods

31 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

HCW Biologics Inc. faces fundamental challenges with weakness in Debt to Equity. The fundamentals warrant careful consideration of downside risks.

Market Cap $7.3M

Dividend Yield —

Revenue Growth -97.9% ↘

Op. Margin None

ROIC -476.1% ↗

FCF / Share $-6.38 ↗

Trailing P/E —

Price / Book 2.6x

FCF Yield —

Debt / Equity 2.46

info Valuation on last close. End-of-day price, Aug 7, 2026.

7-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$54.23K

↓ -97.9% —

Net Income Profit after all expenses

$-7.96M

↑ +73.5% —

Operating Margin Operating profit as % of sales

-224.3%

↓ -57.9% —

FCF / Share Free cash flow per share

$-6.38

↑ +57.3% —

Long-Term Debt Long-term obligations

$0.00

↓ -100.0% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Debt to EquityDebt to Equity is concerning (bottom quartile)
Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns

Financial Health ↑

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Revenue Growth YoY (%)	-97.9% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1324%)	-9.7% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-221%)	-57.7% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-822%)	—	N/M	—	—
EPS Growth YoY (%)	65.7% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-4322.9% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-66.7% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	39.1% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—
Net Income Growth YoY (%)	73.5% Excellent ↑ Excellent Improving Year-over-year change in net income	-20.1% Weak ↑ Weak Improving Year-over-year change in net income	-67.7% Weak → Weak Stable Year-over-year change in net income	-15.8% Weak Weak Year-over-year change in net income	-121.7% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	57.3% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	-1769.2% Weak ↓ Weak Declining Year-over-year change in free cash flow	-38.6% Weak Weak Year-over-year change in free cash flow	1.8% Caution Caution Year-over-year change in free cash flow	—	—	—
Revenue CAGR 3Y (%)	-79.9% Weak Weak Compound annual revenue growth over 3 years	—	-11.5% Weak Weak Compound annual revenue growth over 3 years	—	—	—	—
Revenue CAGR 5Y (%)	-57.9% Weak Weak Compound annual revenue growth over 5 years	—	—	—	—	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Operating Margin (%) (%)	—	—	—	-224.3% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1595%)	—	-142.1% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1047%)	—
Effective Tax Rate (%) (%)	0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—
Profit Margin (%) (%)	—	—	—	-221.7% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1947%)	—	-141.5% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1279%)	—
FCF Margin (%) (%)	—	—	—	-307.4% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	-259.0% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—
FCF / Net Income (x)	1.68x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	0.48x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	1.15x Fair ↓ Fair Declining Free cash flow relative to reported net income Optimal: > 1x	1.39x Good → Good Stable Free cash flow relative to reported net income Optimal: > 1x	0.86x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	1.83x Excellent Excellent Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Return on Invested Capital (%)	-476.1% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-4847.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-130.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-34.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-26.1% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	34.8% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-53.7% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-97.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-90.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-32.2% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-25.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	-37.8% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-287.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-2019%)	—	-185.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1338%)	-39.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-365%)	-25.1% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-268%)	34.7% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+131%)	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Debt to Equity (x)	2.46x Weak ↑ Weak Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Above avg (+310%)	-2.02x Excellent ↓ Excellent Declining Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-437%)	0.47x Good ↑ Good Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-22%)	0.17x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-71%)	0.00x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-100%)	—	—
Interest Coverage (x)	-15.58x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-45.02x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-90.86x Weak Weak Operating income divided by interest expense Optimal: > 5x	-119.05x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—
Net Debt (USD)	$4.86M	$9.02M	$2.71M	$-15.92M	$-11.73M	$-8.46M	$-7.36M
Debt / EBITDA (x)	-0.54x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.48x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.26x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.45x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	0.00x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Revenue per Share (USD)	$0.03	$2.65	$0.08	$0.19	$0.00	—	—
Basic EPS, GAAP (USD)	$-10.63	$-30.96	$-0.70	$-0.42	$-0.69	—	—
Free Cash Flow per Share (USD)	$-6.38	$-14.94	$-0.80	$-0.58	$-0.59	—	—
Book Value per Share (USD)	$1.32	$-6.98	$0.37	$1.04	$2.73	—	—
Tangible Book Value per Share (USD)	$1.32	$-6.98	$0.37	$1.04	$2.73	—	—
Basic Weighted Avg Shares (shares)	2.10M	969,825	35.93M	35.82M	18.77M	—	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Working Capital (USD)	$-18.78M	$-23.93M	$-2.34M	$31.11M	$38.16M	$11.15M	—
LT Debt (USD)	$0.00	$7.38M	$6.30M	$6.41M	$0.00	—	—
Total Equity (USD)	$2.76M	$-6.77M	$13.46M	$37.43M	$51.19M	$-16.72M	$-9.68M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Sales/Revenue/Turnover (USD)	$54.23K	$2.57M	$2.84M	$6.72M	$0.00	$4.10M	—
Depreciation Expense (USD)	$507.02K	$644.62K	$1.14M	$717.85K	$543.60K	$572.87K	—
Net Income, GAAP (USD)	$-7.96M	$-30.02M	$-24.99M	$-14.90M	$-12.86M	$-5.80M	—
Operating Cash Flow (USD)	$-13.39M	$-14.23M	$-22.51M	$-10.39M	$-10.98M	$-10.43M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 26 quarters

HCW Biologics Inc.

Analytical Summary

7-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare HCWB with peers